Towards standardization of next-generation sequencing of FFPE samples for clinical oncology: intrinsic obstacles and possible solutions

[1] Yu KH(2016)Omics profiling in precision oncology Mol Cell Proteomics 24 577-585

[2] Snyder M(2013)From targets to targeted therapies and molecular profiling in non-small cell lung carcinoma Ann Oncol 4 67-81

[3] Thomas A(2015)Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations-a review Transl Lung Cancer Res. 53 852-864

[4] Rajan A(2014)The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: a systematic review and meta-analysis Acta Oncol 16 223-237

[5] Lopez-Chavez A(2016)Prognostic and predictive biomarkers in melanoma: an update Expert Rev Mol Diagn. 1 44-53

[6] Wang Y(2011)The BATTLE trial: personalizing therapy for lung cancer Cancer Discov. 373 726-736

[7] Giaccone G(2015)Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations N Engl J Med 338 221-397

[8] Stewart EL(2012)Genome sequencing identifies a basis for everolimus sensitivity Science 9 389-e501

[9] Tan SZ(2015)Smoothened (SMO) receptor mutations dictate resistance to vismodegib in basal cell carcinoma Mol Oncol. 22 e498-301

[10] Liu G(2015)Does CDKN2A loss predict palbociclib benefit? Curr Oncol. 83 300-3560

[1] Yu KH(2016)Omics profiling in precision oncology Mol Cell Proteomics 24 577-585

[2] Snyder M(2013)From targets to targeted therapies and molecular profiling in non-small cell lung carcinoma Ann Oncol 4 67-81

[3] Thomas A(2015)Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations-a review Transl Lung Cancer Res. 53 852-864

[4] Rajan A(2014)The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: a systematic review and meta-analysis Acta Oncol 16 223-237

[5] Lopez-Chavez A(2016)Prognostic and predictive biomarkers in melanoma: an update Expert Rev Mol Diagn. 1 44-53

[6] Wang Y(2011)The BATTLE trial: personalizing therapy for lung cancer Cancer Discov. 373 726-736

[7] Giaccone G(2015)Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations N Engl J Med 338 221-397

[8] Stewart EL(2012)Genome sequencing identifies a basis for everolimus sensitivity Science 9 389-e501

[9] Tan SZ(2015)Smoothened (SMO) receptor mutations dictate resistance to vismodegib in basal cell carcinoma Mol Oncol. 22 e498-301

[10] Liu G(2015)Does CDKN2A loss predict palbociclib benefit? Curr Oncol. 83 300-3560